Diazoxide‐induced pulmonary hypertension in hyperinsulinaemic hypoglycaemia: Recommendations from a multicentre study in the United Kingdom

• DOI: 10.1111/cen.14096
• Publication Date: 2019-09-14T13:38:40Z
• Authors: Suet Ching Chen; Antonia Dastamani; Donatella Pintus; Daphne Yau; Sommayya Aftab; Louise Bath; Craig Swinburne; Lindsey Hunter; Alessandro Giardini; Georgi Christov; Senthil Senniappan; Indraneel Banerjee; Mohamad Guftar Sh...; Pratik Shah
• Keywords: Diazoxide

Diazoxide is first-line treatment for hyperinsulinaemic hypoglycaemia (HH) but diazoxide-induced pulmonary hypertension (PH) can occur. We aim to characterize the incidence and risk factors of PH in a large HH cohort provide recommendations anticipating preventing diazoxide-treated patients with HH.Retrospective study involving four UK regional centres; review case notes on diazoxide.The diagnosis was based clinical echocardiography evidence. Patient treatment-related were analysed association.Thirteen (6 men) 177 developed PH, an 7%. In group, diagnosed at median (range) 9 (1,180) days, diazoxide commenced 4 (0,76) days from reaching maximum dose 7 (2.5,20) mg/kg/d. The majority (8 13 patients) within 2 weeks diazoxide. Complete withdrawal, not reduction, led resolution 41 (3,959) days. three patients, continued beyond 12 months. Risk development included presence congenital heart disease (CHD) (P = .008), total fluid volume exceeding 130 mL/kg/d immediate 24 hours preceding .019).Pulmonary occur 7% patients. include overload. Recommendations restriction prior discontinuation if develops.